Abstract: Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)based approach can be enhanced by combining the PDT with an anti-FasL factor, for example, an anti-FasL neutralizing antibody.

Abstract: An aqueous pharmaceutical composition comprising a peptide and one or more water-soluble or water-dispersible gelling agents.

Abstract: Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The solution is for treating a mammal suffering from one or more of pain, inflammation, fever, acute mastitis, diarrhea, lameness, locomotor deficiency, or respiratory illness.

Abstract: The invention relates to amphiphilic derivatives of a triazamacrocyclic compound, as well as to said derivatives as active molecule transporters. The invention also relates to a nanodrug including at least one amphiphilic derivative of a triazamacrocyclic compound and at least one active molecule of a protein such as an antibody, in particular for the treatment of autoimmune diseases or for the treatment of cancer.

Abstract: The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug.

Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).

Abstract: A compound is provided that has the formula (II): where R1 in each occurrence is independently H, or C1-C4 alkyl; R2 is a nullity or CH—CH3, R3 is a nullity or C(O)—R6—NH; R6 is C2-C6 alkyl, (CH2CH2—O)n, or (CH(OH)CH2)n; n is an integer of between 1 and 4; R4 is a nullity or NH—R6—C(O); and R5 is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine, blood brain barrier (BBB) peptide, membrane translocating peptide, TAT peptides, endocannabinoids 1 & 2, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptide transferrin, glucosyl ester, lactic acid, leucine, tryptophan, glutamic acid.

Abstract: The present invention relates to Factor IX polypeptides conjugated to heparosan (HEP) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used—for example—in the treatment or prevention of bleeding disorders such as haemophilia B.

Abstract: This invention discloses drug-delivery compositions, methods of making prodrugs, and methods of drug delivery using a self-assembled gelator. The backbone of the gelator can contain a drug or prodrug, such as acetaminophen or salicin. Additional drugs or agents can be encapsulated in the gelator. Enzymatic or hydrolytic cleavage can be used to release the drugs.

Abstract: A targeted therapeutic agent comprising a compound of formula I: B-L-D??(I), wherein: B is a low molecular weight binding moiety for Carbonic Anhydrase IX (CAIX); D is a drug moiety; and L is a linker group that undergoes cleavage in vivo for releasing said drug moiety in an active form. The drug moiety is suitably a cytotoxic agent for targeted delivery to cancer cells expressing CAIX. The binding moiety B suitably comprises a sulfonamidothiadiazole moiety. The binding moiety B may comprise one, two or more groups capable of binding to CAIX. The linker group suitably comprises a disulfide bond and/or a triazole group and/or a cleavable peptide group.

Abstract: Isatoic anhydride derivatives having an N-substituent which includes a quaternary ammonium group are useful for labeling and/or functionalizing a target material and/or for coupling materials together. The isatoic anhydride derivatives of the present disclosure can be advantageously water soluble, easily prepared and purified. Isatoic anhydride derivatives useful in the present disclosure preferably have at least one chemically reactive group or at least one binding group or at least one detectable label. Anthranilate derivatives made from the isatoic anhydrides derivatives or otherwise and kits including the isatoic anhydride derivatives are also disclosed.

Abstract: Described herein are drug delivery conjugates for targeted therapy. In particular, described herein are drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids that are useful for treating cancers and inflammatory diseases. In some embodiments, the cancer is selected from the group consisting of a carcinoma, a sarcoma, a lymphoma, Hodgekin's disease, a melanoma, a mesothelioma, Burkitts lymphoma, a nasopharyngeal carcinoma, a leukemia, and a myeloma.

Abstract: The invention provides a controlled release biodegradable polymer formulation adapted for administering bioactive agents, such as therapeutic proteins, to a patient through implantation of a bolus that forms a depot within the patient's body tissues. The formulation includes a dehydrated inclusion complex of the bioactive agent within a hydrogel. A method of forming the inventive formulation is also provided, as well as a method for using the formulation in the treatment of a malcondition in a patient in need thereof.

Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.

Abstract: Modified relaxin polypeptides and their uses thereof are provided

Abstract: Conjugates of an IL-15 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to an individual.

Abstract: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.

Abstract: Described herein are modified host cells useful in the production of bioconjugates that can be used to vaccinate subjects against infection with Pseudomonas. The genomes of the modified host cells described herein comprise genes that encode proteins involved in glyosylation of proteins as well as genes specific to the production of Pseudomonas-specific antigens.

Abstract: IgA-based Fc-folate conjugates as a treatment for cancer are provided. The conjugates utilize only the Fc portion of IgA to target its receptor on neutrophils (Fc?R1) to elicit antibody-dependent cellular-cytotoxicity (ADCC).

Abstract: The present invention provides compositions and methods for targeting an extracellular matrix derived (EMD) peptide predominantly to an injured tissue, as opposed to an uninjured tissue in vivo. The targeted EMD peptide facilitates the repair and/or regeneration of the injured tissue by providing a surface for cells to attach and grow, thereby facilitating the repair and/or regeneration of the injured tissue.

Abstract: This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Müllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Müllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.

Abstract: Disclosed herein are compositions and nanoconjugates comprising a micelle construct; an antibody single chain fragment variable (scFv); a NF-kb inhibitor; and a topoisomerase II inhibitor. Further disclosed herein are methods of delivering a drug molecule to a tumor site of a subject comprising: attaching the drug molecule to a targeted micelle, wherein the targeted micelle comprises a micelle construct and an antibody single chain fragment variable (scFv); and delivering the drug molecule attached to the targeted micelle to the tumor site through intracellular delivery. Also disclosed herein are methods of treating cancer or inhibiting tumor cell growth comprising administering to a subject in need thereof, a therapeutically effective dosage of a composition comprising a micelle construct, an antibody single chain fragment variable (scFv), a NF-kb inhibitor, and a topoisomerase II inhibitor.

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L1-L2-LP-NH—(CH2)n1-La-Lb-Lc or -L1-L2-LP- wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the terminal Lc or LP with the nitrogen atom of the amino group at position 1 as the connecting position.

Abstract: Methods of treating patients having HER2-positive, operable, locally advanced or inflammatory breast cancer with the antibody-drug conjugate Trastuzumab-MCC-DM1 and Pertuzumab are provided.

Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection and diagnosis of early stage pancreatic cancer. In preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay can detect a marker for early stage pancreatic cancer in serum. More preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

Abstract: The present invention relates to reverse-micellar systems comprising at least an active agent, an acylglycerol, a sterol, lecithin, ethanol and water, for use in chelation and/or sequestering of a radionuclide and/or a metal in a patient. The invention also relates to the reverse-micellar systems and to pharmaceutical compositions comprising said reverse-micellar systems.

Abstract: The present invention relates to the preparation and use of reversibly PEGylated nanocarriers. The reversibly PEGgylated nanocarrier system comprises an inner core comprising or consisting of a nanoparticle and/or at least one pharmaceutical compound; optionally at least one lipid bilayer on the surface of the inner core; a first ligand bound to the surface of said inner core, or if present, to the surface of the at least one lipid bilayer; a second ligand bound to the first ligand, the second ligand being covalently bound to poly(ethylene glycol) or a derivative thereof. The reversibly PEGgylated nanocarrier system is characterized in that binding of the second ligand to the first ligand is non-covalent and reversible. Pharmaceutical compositions and use of such compounds and compositions in the field of e.g. cancer therapy, gene therapy, inflammatory diseases and pain therapy are also disclosed.

Abstract: The present disclosure relates to a solid dispersion of amorphous cobicistat and methods of its preparation. Cobicistat may be complexed with a pharmaceutically acceptable carrier such as ?-cyclodextrin or hydroxy! propyl ?-cyclodextrin. The present disclosure also provides pharmaceutical formulations for administration to patients and methods of their use.

Abstract: The invention in suitable embodiments is directed to using purified, non-cage clathrin protein for purposes of assisting in drug discovery and development. In one aspect, a tool composition, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more protein sequence, forms one or more type of tool for carrying out various elements and activities of drug discovery and development.

Abstract: A nanosensor-containing polymer composition for the monitoring of physiological parameters and a method for making the composition are disclosed. The composition includes a fluid nanosensor-containing polymer that becomes rigid in the presence of physiological conditions. In the fluid form, the composition can be suitable for injection on to or into the skin. In the rigid form, the nanosensor is substantially immobilized in the polymer. The method includes forming a mixture comprising a nanosensor and polymer precursor(s), subjecting the mixture to conditions suitable for forming the fluid form of the composition; and subjecting the fluid form to physiological conditions to provide a rigid nanosensor-containing composition.

Abstract: Disclosed are novel cell-penetrating transporters for enhancing cellular uptake of peptide fusion proteins into live cells. The cell-penetrating transporters comprise a functionalized peptide construct comprising a cell importation peptide covalently bound to a cargo, the cell importation peptide in an unreactive monomeric form, and a pharmaceutical carrier. In certain embodiments, the cargo further comprises a nuclear localization sequence (NLS) allowing the cargo to be transported across the nuclear membrane.

Abstract: The invention provides a conjugate with fluorochrome moiety F coupled to a targeting moiety T. Moiety F is described by formula (I), and the targeting moiety T is characterised in that it has affinity to a tumour marker, such as an antibody or antibody fragment. The conjugate may be used for tumour diagnostics including photodetection of tumour nodules during resection surgery.

Abstract: The present invention relates to new molecular design that allows micelles to report their activation and disassembly by an enzymatic trigger. The molecular design is based on introduction of a labeling moiety selected from a fluorescent dye, a dark quencher, combinations of dyes or dyes/quenchers, and a fluorinated moiety (a 19F-magenetic resonance (MR) probe for turn ON/OFF of a 19F-MR signal) through covalent binding to the focal point of amphiphilic polymer-dendron hybrids with the labeling moiety. At the assembled micellar state, the dyes are closely packed and hence the probability for intermolecular interactions increases significantly, leading to alteration of the fluorescent properties (signal quench or shift) or the 19F-MR signal (OFF state) of the micelles. Upon enzymatic cleavage of the hydrophobic end-groups from enzyme-responsive dendron, the polymers become hydrophilic and disassemble.

Abstract: The present invention provides a method of treating cancer with a proteasome inhibitor. The invention provides a method for treating a patient with a proteasome inhibitor based on measurements of tumor features using biomedical imaging techniques. The invention also provides a method of treating a patient with cancer based on levels of GLUT4, as measured by a biomedical imaging technique. The invention also provides a method of treating a cancer patient with a proteasome inhibitor based on the effect of the treatment on tumor features measured by a biomedical imaging technique.

Abstract: The shoe sole sanitizer provides a UV radiation emitting system that kills microbial pathogens deposited on shoe sole surfaces. The system includes a housing containing at least one UV radiation source. Bottom and side portions of the housing are opaque to provide a UV shield while directing the UV upward towards a top housing portion. The top housing portion has a plurality of holes forming an approximate shape of two shoe sole bottoms. The holes allow the UV radiation to escape the housing and target sole surfaces disposed on and over the exterior of the housing top. Each shoe sole approximation area has a pivotal tang that extends therefrom. Shutters attached internally to the tangs extend or limit UV exposure from the top surface depending on the size of the sole disposed on the top. The system is powered by standard AC electrical power or battery sources.

Abstract: An apparatus for inspecting empty containers in order to detect dirt therein is disclosed. A radiation source generates exciting radiation, and the exciting radiation is directed onto the inner wall of a container and excites dirt to be detected in such a way that the dirt emits luminescent radiation. At least one device detects the luminescent radiation emitted by the dirt, and another device analyzes the detected luminescent radiation. Also disclosed is a corresponding method for inspecting empty containers in order to detect dirt therein.

Abstract: Embodiments relate generally to systems and methods for treating passenger transportation vehicle cabin surfaces and surrounding air. The methods may use organic LEDs to produce ultraviolet light. Systems may be provided to ensure safety and operation of the air treatment only when passengers and personnel are not present in the cabin.

Abstract: A system and method for modifying monoatomic oxygen levels in an initial fluid, for applications. The system and method produces both positive and negative oxygen modified fluid that retains oxygen levels for long durations as measured by oxygen reduction potential (ORP). An incoming fluid is split between a positive chamber defined by a cathode and a porous divider and a negative chamber defined by the porous divider and an anode. The relative charge over the porous divider produces fluid with elevated ORP from the positive chamber and fluid with lowered ORP from the negative chamber. A method of killing bacteria includes contacting the bacteria with negative ORP fluid produced in the system and method to the bacteria.

Abstract: A gas transfer system including a housing, a pressurized gas canister held by the housing, a first passageway in fluid communication with the pressurized gas canister and configured to supply pressurized pre-sterilization gas from the pressurized gas canister to a fluid flow component, a gas discharge canister held by the housing; and a second passageway in fluid communication with the gas discharge canister and configured to supply post-sterilization gas from the fluid flow component to the gas discharge canister. Additional related devices, systems and methods are provided.

Abstract: The invention relates to a system, methods and apparatus for efficiently and cost-effectively preventing the transfer of microbes, such as, for example, bacteria and viruses seamlessly during commercial transactions typically occurring at a full service check-out station in a large retail store. The invention further considers the application of the methods and apparatus in other industrial disciplines where, for example, medical equipment and surgical tools may be susceptible to cross-contamination of microbes. One preferred embodiment incorporates a slide able drawer within a cash box where currency is stored, taken, or added randomly over a period of time. Especially designed lamps allow for a rapid switching means to control the time period for activating or deactivating lamps, thus regulating UV exposure. Exposure time with UVC and the orientation of the UV lamps provides complete germicidal decontamination within seconds.

Abstract: An aerosol generator includes a composite conduit to transport multiple liquids to a heating element at flow rates such that the liquids arrive at the heating element in desirable concentrations. The heating element volatilizes the liquids to form volatilized fluid, which mixes with ambient air to form an aerosol with desirable concentrations of the multiple liquids.

Abstract: A modular, integrated, combination air purification and aroma diffuser includes a UV and catalytic oxidation germicidal cell and multiple filtrations as pre-treatment of air diffusing essential oils or other liquids as ultra-fine droplets entrained in airflow into enclosed, habitable spaces. Liquid microbicide, insecticide, fumigant, or aroma therapy is kept cleaner by eradication of microbes. Comparatively larger droplets are separated out and recycled to the reservoir after initial atomization. An electrical module, between a purifier and filters upstream and a diffuser downstream, includes a pump, a fan, and a controller for both. Staged, double-eduction, triple-separation processes include a micro-cyclone for quiet, well diffused flow of ultra-fine droplets.

Abstract: A photo-catalyzing fluid mobilizing system and method are disclosed. A chamber has a power source. A fluid mobilizer is mounted in the chamber and connected with the power source to mobilize a fluid through the chamber. The fluid mobilizer includes one or more fan blades that are coated with a photo catalyst. A UV light source is mounted in the chamber proximate the fluid mobilizer and connected with the power source to catalyze the photo catalyst coating the blades to purifier the fluid being mobilized thereover.

Abstract: An air filtration media for use with a heating ventilation and air condition (HVAC) system is provided. The filtration media comprises an air filter media layer having a first and second side, a PCO media layer having a first and second side, and a barrier layer positioned between the second side of the air filter media layer and the first side of the PCO media layer. The air filter media layer, barrier layer, and PCO layer are pleated together and enclosed within a frame for placement adjacent a light source within a plenum of the HVAC system.

Abstract: A treatment of a wound involving the topical application of probiotics defined as beneficial microorganisms or cellular nutrients in cooperation with a hydrophobic wound dressing designed to bind microorganisms.

Abstract: A method of inhibiting bleeding from an open surgical site includes mixing (i) a flowable gel solution comprising a biopolymer dissolved in a first solvent and (ii) a flowable hardener solution comprising a cross-linking agent dissolved in a second solvent to form a flowable hemostatic gel composition. The method also includes applying the flowable hemostatic gel composition to the open surgical site. The cross-linking agent links chains of the biopolymer together to form a solid hydrogel that inhibits bleeding from the surgical site.

Abstract: Adhesive compositions and patches, and associated systems, kits, and methods, are generally described. Certain of the adhesive compositions and patches can be used to treat tissues (e.g., in hemostatic or other tissue treatment applications), according to certain embodiments.

Abstract: Disclosed are phospholipid based compositions and implant devices, as well as methods and kits that include such compositions or components thereof. In particular, the present compositions include a polymer component such as a poloxamer or PEG component and a phospholipid component, such as a Phosal. The present compositions may include at least one additional component, such as granules, powder and/or particulates. The present compositions may further include one or more bone graft materials and/or active ingredients. The compositions may be used on their own or incorporated on or in a surgical implant.

Abstract: Provided herein are biodegradable poly(ester amide) elastomers, methods of making the elastomers, and methods of using the elastomers, for example for tissue engineering. The elastomers can be used for preparation of tissue prostheses, such as a heart valve leaflet, a heart valve, cartilage, myocardium, blood vessels, smooth muscle, skeletal muscle, or other tissues. Also provided herein are semiquantitative FTIR methods for determining structure of a poly(ester amide) elastomer.